Most Patients With Early-Stage Classical Hodgkin Lymphoma Achieve Complete Response With Brentuximab Vedotin Combination

Brentuximab vedotin with nivolumab and standard chemotherapy agents produced a nearly 100% overall response rate in patents with early-stage classical Hodgkin lymphoma.

Related Keywords

United States ,Switzerland ,Lugano ,Ticino ,Germany ,Massachusetts ,Roger Dansey ,Jeremy Abramson ,Bristol Myers Squibb ,International Conference On Malignant Lymphoma ,Jo Ann Hagler Center ,German Hodgkin Study Group ,Seagen Inc ,European Hematology Association ,International Conference ,Malignant Lymphoma ,Massachusetts General Hospital ,Lymphoma Response ,Immunomodulatory Therapy Criteria ,Chief Medical Officer ,